Using targeted IL-2 to improve immunity against respiratory viruses
Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection
This study is looking at a new treatment that uses a special type of medicine to help people with serious flu infections by calming down their immune system when it goes into overdrive, and it might also boost the effectiveness of flu vaccines for better protection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-10899505 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment using targeted IL-2 to help patients with severe respiratory viral infections, particularly those caused by the influenza A virus. The approach aims to reduce harmful immune responses, known as immunopathology and cytokine storms, that can occur during severe infections. By enhancing the body's immune response, this treatment could be initiated even at later stages of infection, potentially improving patient outcomes. Additionally, the research explores using IL-2 as an adjuvant to strengthen immunity following vaccination against influenza.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults experiencing severe respiratory distress due to influenza A virus infections.
Not a fit: Patients with mild respiratory infections or those who do not have influenza A virus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for severe respiratory viral infections, improving recovery and reducing complications.
How similar studies have performed: Previous research has shown promise in using IL-2 for enhancing immune responses, suggesting potential success for this novel application.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Strutt, Tara Marlene — University of Central Florida
- Study coordinator: Strutt, Tara Marlene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.